Introduction
At the latest since the resolution of the German parliament on Jan uary 19, 2017 to ament the German Narcotic Drugs Act (Betäu bungsmittelgesetz, BtMG ) with regard to the treatment of severe ly ill patients with highquality cannabis medications (documents 18/8965 and 18/10902 of the German parliament), there has been growing public interest in the therapeutic properties of cannabis. Until then, an exemption of the Federal Institute for Drugs and Medi cal Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) was required to allow for treating patients with cannabis products. Until 2016, such exemptions had been issued for about 1000 patients (www.bundestag.de). While so far patients had to pay for this treatment themselves, the new amendment now regulates the covering of treatment costs by health insurance companies.
Besides the change of the legal status, scientific interest in the po tential therapeutic properties of cannabis has been growing, driven by advances in the understanding of the endocannabinoid system. The isolation of cannabinoid receptors and endogenous can nabinoids in the nervous system by Raphael Mechoulam [1] and other groups and the discovery that the endocannabinoid system is capable of modulating numerous physiological processes, such as pain, eating behavior, memory, and mood [2, 3] have paved the way for systematic research into the effects of cannabis on a vari ety of chronic diseases [4] [5] [6] [7] . Data from clinical studies supported a role of cannabis and endocannabinoids in the treatment of spe cific symptoms, such as spasticity and central or spasticity-associ ated pain in patients with multiple sclerosis, chemotherapyin duced nausea, and anorexia [7] . Until recently, the only medicines of this class approved in Germany were the combination drug Sa tivex® as an addon therapy for adult multiplesclerosis patients with moderate to severe spasticity, and the synthetically manufac tured tetrahydrocannabinol analogue nabilone (Canemes®) for the treatment of adult cancer patients suffering from chemother apy-induced nausea. Since March 10, 2017 cannabis flowers and
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Due to the changing legal status of medical cannabis and de rivatives in numerous countries, this therapeutic option has moved into the field of public debate. Neurologists treating patients with idiopathic Parkinson's disease are increasingly confronted with questions regarding cannabis as a treatment alternative, especially for levodoparesistant Parkinson's symp toms. A number of single case reports and case series suggest ed improvement of Parkinsonian symptoms after cannabinoid intake, but the small number of available randomized clinical trials failed to reproduce the extent of these findings. Only one trial found a reduction of levodopainduced dyskinesia with cannabinoid treatment, the remaining three trials showed no effect on Parkinsonian symptoms. This article gives an overview on the effects of cannabis, and reviews experimental and clin ical trials studying the effects of cannabinoids in idiopathic Parkinson's disease. their extracts can be prescribed on a narcotic drug prescription form without limitation to specific indications [8] .
The discovery of high concentrations of cannabinoid receptors in the basal ganglia triggered an increasing interest in the thera peutic potential of cannabinoids for the treatment of Parkinson's disease (PD) and other movement disorders. Public awareness of this topic was raised by anecdotal reports of considerable improve ment of PD symptoms after cannabis consumption that were shared via social networks and published in the general press. For example, Larry Smith, a USAmerican PD patient claiming improve ment of his dyskinesia with cannabis consumption, attracted broader public attention via YouTube TM [9] . In Germany, cannabis consumption to alleviate PD symptoms gained attention when the topic was raised in the German TV drama series "Lindenstrasse" (the German equivalent to the British TV drama series "Coronation Street") [10] .
Cannabis and the Endocannabinoid System
Cannabis is a mixture of more than 60 substances, referred to as phytocannabinoids due to their plant origin (as opposed to endo cannabinoids produced by the human body). The main active con stituents of cannabis are the psychotropic cannabinoid delta9tet rahydrocannabinol (THC) and the nonpsychotropic cannabinoid cannabidiol (CBD). These substances were isolated in the 1960s and proven to be active components of cannabis [1, 11] . In the 1990s, the two most important receptors -the cannabinoid re ceptor 1 (CB1R) [12] and the cannabinoid receptor 2 (CB2R) [13] -and their endogenous ligands, such as anandamide and 2ara chidonylglycerol (2AG), and hence the endocannabinoid system (ECS) were discovered.
CB1R is primarily located in the nervous system (except for the thalamus and brain stem), with high concentrations in the hippocam pus, the association cortex, cerebellum, basal ganglia, and spinal cord (here with high concentration in the dorsal roots), and peri pheral nerves [7] . CB2R is expressed in the gastrointestinal tract, in lymphatic tissue and peripheral nervous system. However, in 2014 it was shown that CB2R is also expressed in the CNS, primarily in neurons of the dorsal nucleus of the vagus nerve, the nucleus am biguus, in the spinal trigeminal nucleus, and on microglia [14] [15] [16] .
CB1R and CB2R are G proteincoupled receptors and via the G 0 /G i unit inhibit the activity of the adenyl cyclase, thereby influ encing the release of excitatory neurotransmitters, such as gluta mate, dopamine and acetylcholine. In addition, other transmitter systems, such as the NMDA (NmethylDaspartate) and the sero tonin, the opioid and GABA (γ-aminobutyric acid) systems are also modulated via indirect mechanisms [7] . Furthermore, the mito genactivated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway is activated via the G βγ complex [17] [18] [19] , a pathway that has regulatory properties regarding cell develop ment, cell differentiation and apoptosis [20] .
The structural analysis of cannabinoid receptors ultimately paved the way for the development of synthetic cannabinoids. Today, several cannabinoidbased preparations are available for medicinal use (▶table 1). 
Parkinson's Disease and Neuroprotection in Experimental Studies
In the late 1960s and early 1970s, early animal studies demonstrat ed an effect of cannabinoids on the catecholaminergic and dopa minergic systems [21, 22] . CB1R and the endocannabinoid ligands anandamide and 2AG occur in high concentrations in the dopa minergic system, including the striatum [23] , where they modu late dopaminergic transmission as a retrograde feedback system on presynaptic glutamatergic and GABAergic nerve endings. Invit ro studies in the late 1970s generated conflicting evidence, demon strating both an increase [24] and a dosedependent decrease of dopamine synthesis [25] and release [22] . Invivo studies showed an increase in dopamine release in the prefrontal cortex, striatum, but also in the nucleus accumbens. Thus, an increased firing rate of dopaminergic neurons after acute THC exposure can be as sumed, resulting in augmented dopamine synthesis and release. Interestingly, acute and chronic THC exposure seems to result in different effects on neuronal firing rate, transmitter synthesis, trans mitter release and reuptake within the dopaminergic system [26] . An increase in ECS activity was detected both in a PD animal model and in human tissue analyses from PD patients [27] , includ ing an upregulation of cannabinoid receptors [28, 29] , an accumu lation of cannabinoid receptor agonists [30, 31] and a reduction in their degradation [32] . This adaptation of the ECS was reversed by chronic levodopa substitution in an animal model [33] .
With regards to the effect of CB-1R on motor function, experi mental studies yielded heterogeneous and partially conflicting re sults. Direct activation of CB1R reduced dopamine release and re sulted in an increase in bradykinesia, shown in the MPTP (1me thyl4phenyl1,2,3,6tetrahydropyridine) animal model of PD [34] . Others reported improvement of motor impairment with canna binoid receptor agonists, possibly due to receptorindependent mechanism of action [35, 36] . Furthermore, alleviation of levodo painduced dyskinesia has been reported for cannabinoid receptor agonists and antagonists [31, 37] .
In addition, ECS activation may confer neuroprotective such as direct receptorindependent mechanisms [38] , activation of an ti-inflammatory cascades in glial cells via CB-2R [39, 40] , and an tiglutamatergic and thus antiexcitotoxic properties [41] .
Clinical Research
Numerous case series and single case reports concluded that can nabinoids might have potential beneficial effects on PD symptoms.
In a large survey with 339 Czech PD patients, about 25 % of the respondents stated to regularly consume cannabis as an addon therapy. Of these 85 patients, 39 (46 %) reported general improve ment of their PD symptoms. 26 patients (31 %) reported a reduc tion of resting tremor, 38 patients (45 %) an improvement of brady kinesia, 32 patients (38 %) a decrease in muscle rigidity, and 12 pa tients (14 %) reduction of levodopainduced dyskinesia [42] .
An observational study from Israel involving 22 PD patients showed a reduction of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score of 30 % thirty minutes after patients smoked cannabis. In addition, pain and sleep quality improved under long term therapy with cannabis [43] . A very early and small case series from London with 5 PD patients evaluated the effect of cannabis smoking on resting tremor but found no improvement [44] .
In contrast to the clearly positive effects described in single case reports and case series, data from randomized placebocontrolled trials (RCTs) on effects on PD motor symptoms are less encourag ing. So far, 4 RCTs evaluating the effects of cannabinoids on alto gether 49 PD patients have been published.
In a study by Chagas et al., PD patients were randomized to re ceive CBD daily in doses of either 75 mg, 300 mg, or placebo, with 7 patients randomized into each group. After 6 weeks, motor func tion (UPDRS motor score) and quality of life (Parkinson's Disease Questionnaire PDQ39) were assessed and compared to baseline. The improvement in PDQ-39 sum score was significantly higher in patients treated with 300 mg/day of CBD, while UPDRS scores did not differ between groups [45] .
A study from Manchester evaluated the effect of nabilone, a CB1R and CB2R agonist, on levodopainduced dyskinesia in 7 pa tients in a crossover design. A total dose of 0.03 mg/kg body weight was administered with half the dose 12 h before the remainder 1 h before an acute levodopa challenge, which then was repeated 14 days later when groups had been crossed over. Dyskinesia duration and severity were significantly reduced in the nabilone group. How ever, no change in the severity of PD symptoms and no difference in motor improvement after the acute levodopa challenge were observed. In the nabilone group, 5 of 7 patients experienced mild sedation, dizziness, hyperacusis, disorientation, and scenic visual hallucinations [46] .
Caroll et al. studied the effect of Cannador®, a whole-plant ex tract with defined THC content and a THC to CBD ratio of about 2:1, on 17 PD patients. Over a period of 4 weeks, increasing doses of Cannador®, were administered b.i.d., up to a maximum THC daily dose of 0.25 mg/kg. Despite the doubleblind design, 71 % of patients correctly identified their respective treatment arm. Nei ther levodopainduced dyskinesia (assessed with UPDRS dyskine sia score and Rush Dyskinesia Rating Scale) nor UPDRS motor scores, PDQ39 or sleep quality improved. In contrast, a (nonsig nificant) trend towards an increase of dyskinesia severity with Can nador® treatment was observed [47] .
In 2004, Mesnage et al. studied the CB1R antagonist rimona bant, among others, and its effect on PD symptoms. Over a period of 16 days, 4 patients received 20 mg/day of rimonabant. At the end of period, neither UPDRS motor scores nor UPDRS dyskinesia scores changed significantly [48] .
To date, only one other study investigating the effect of CBD on PD tremor has been registered (NCT02818777), aiming at recruit ing 60 patients.
Psychotropic and Cardiovascular Side Effects
Considering the increased prevalence of psychotic symptoms in patients with idiopathic Parkinson's disease, psychotropic effects of cannabis and cannabinoids are of special interest (Chang and Fox 2016). In a study by Sieradzan and colleagues, 5 of 7 PD patients treated with the THC analog nabilone experienced psychotropic side effects such as scenic visual hallucinations [46] . In the study of Lotan et al., 6 of the initially included 28 patients (21 %) with an av erage age of 65 years dropped out due to psychotic symptoms fol lowing cannabis consumption [43] .
The primary active component responsible for the psychotro pic effect of cannabis is THC. In clinical studies investigating the ef fects of CBD, no psychotic side effects were observed [45] . In an openlabel study, 6 PD patients with psychiatric plus symptoms, such as illusions and hallucinations, and minus symptoms, such as withdrawal and depression, received CBD over a period of 4 weeks. Treatment was started with an initial daily dose of 150 mg and grad ually increase over a period of 1 month up to a maximum daily dose of 400 mg [49] . The authors reported a significant reduction in psy chotic symptoms, as measured with the Parkinson Psychosis Ques tionnaire (PPQ) and the Brief Psychiatric Rating Scale (BPRS).
Apart from psychotropic effects, cannabinoids are associated with adverse cardiovascular events. Nonmotor PD symptoms in clude orthostatic hypotension caused by sympathetic cardiac den ervation, among others [50] . Similarly, cannabis consumption can also lead to an orthostatic drop in blood pressure and even ortho static syncope [51] . Due to sympathetic cardiac denervation, the ability to counteract a drop in blood pressure by increasing the heart rate is limited in PD patients. This, in turn, may intensify the impact of cannabinoids on orthostatic dysregulation. The study of Sieradzan et al. detected an orthostatic drop in systolic blood pres sure in all patients. One patient in the nabilone group was unable to continue the study due to symptomatic orthostatic hypotension [46] . Furthermore, the increased sympathetic activity with canna bis consumption results in an increased myocardial oxygen de mand. In patients with preexisting angina pectoris, exercise symp toms of myocardial hypoxia occur earlier with cannabis consump tion [52, 53] . In addition, the risk of myocardial infarction is increased by 1 to 4.8 fold in cannabis users [54, 55] . With the pos sibility of cardiac comorbidities in PD patients, these adverse events should receive additional attention.
Conclusion
In summary, the positive effects of cannabinoid consumption on motor symptoms in patients with Parkinson's disease described in single case reports and case series have not been confirmed by the few placebocontrolled studies available as yet. Results of studies on cannabinoids for the treatment levodopainduced dyskinesia have been inconsistent. The postulated beneficial effects of can nabinoids are opposed by potential side effects, such as hallucina tions and orthostatic hypotension, which require special attention in PD patients.
Therefore, the clinical use of cannabinoids in patients with Par kinson's disease should be preceded by careful individual riskbene fit assessments. Currently, it should be limited to symptoms for which positive effects can be expected from other indications for cannabinoids, such as refractory pain or sleep disorders. In view of the extended approval of cannabinoids, further controlled studies are urgently needed to provide data that support evidencebased treatment recommendations, and to increase confidence in the safety of prescribing cannabinoid therapies. 
